Carisma Therapeutics Investor Relations Material

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies using its proprietary macrophage and monocyte cell engineering platform. The company's primary aim is to create treatments for cancer and other serious diseases by leveraging engineered macrophages and monocytes to attack and eliminate tumor cells. Carisma's product candidates include ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) and CAR-macrophage (CAR-Macrophage) cellular therapies designed to treat solid tumors that overexpress specific markers such as HER2. The company is headquartered in Philadelphia, PA, and its shares are listed on the NASDAQ.